Drugs / cyclosporine A (CsA)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04328727 Background | Nov 2020 → Jun 2022 | aplastic anemia | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cyclosporine A (CsA) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04328727 ↗ |
| Route | Oral | “CsA was administered orally every 12 h at a starting dose of 3-6 mg/kg/day” NCT04328727 ↗ |